You are here:HomeLive TVVideosOral Insulin Can Be A Blockbuster Opportunity: Kiran Mazumdar-shaw

Oral insulin can be a blockbuster opportunity: Kiran Mazumdar-Shaw

loading..

Biocon has just brought in Bristol Meyers as a partner for its oral insulin drug. Bristol will fund the clinical trials and, if successful, the rest of the deal will be triggered. Kiran Mazumdar-Shaw, CMD, Biocon, is hopeful of the same and thinks this is a blockbuster opportunity.


Social Sharing

Advertisement

Advertisement

Portfolio
 

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2014. All rights reserved.